What is baricitinib? What are its main ingredients and therapeutic uses?

Baricitinib is an oral Janus kinase (JAK) inhibitor that mainly works by inhibiting the JAK1 and JAK2 signaling pathways. This mechanism allows it to attenuate immune system-related disease responses, reduce inflammation and immune responses, thereby alleviating patient symptoms. Baricitinib was initially approved for the treatment of rheumatoid arthritis, but its scope of application has gradually expanded to become a treatment option for a variety of immune diseases.

The main component of baricitinib is baricitinib (Baricitinib) itself, which is a small molecule drug. It modulates the inflammatory response in the immune system by selectively inhibiting the activities of JAK1 and JAK2. This mechanism of action enables baricitinib to effectively intervene in inflammatory processes caused by abnormalities in the immune system, such as rheumatoid arthritis and other immune-mediated diseases. Baricitinib's regulatory effect on the immune response makes it an important drug in the treatment of immune system diseases.

The most widespread therapeutic use of baricitinib is in the treatment of rheumatoid arthritis (RA), particularly in patients who have failed to respond to conventional disease-modifying drugs (DMARDs) or biologics. As a JAK inhibitor, baricitinib can reduce joint pain, swelling and stiffness and improve joint function. It is often used in combination with other treatments, such as methotrexate, to help control disease activity and improve a patient's quality of life.

In addition, baricitinib is also used to treat severe or moderately severe cases caused by COVID-19 (COVID-19), especially those with high inflammatory response. In this case, baricitinib helps reduce the immune system's overreaction and reduce immune damage caused by viruses by inhibiting the JAK signaling pathway. Baricitinib is approved as a treatment for COVID-19, particularly in settings where anti-inflammatory therapy is needed, and has been shown to reduce mortality and prolonged illness in hospitalized patients.

Reference materials:https://www.mims.com/hongkong/drug/info/baricitinib?mtype=generic